The lower prevalence of HBV DNA seen in anti-HBc seropositive donors provides indirect evidence the preponderance of HBV DNA in anti-HBc seronegative donors will be much lower

The lower prevalence of HBV DNA seen in anti-HBc seropositive donors provides indirect evidence the preponderance of HBV DNA in anti-HBc seronegative donors will be much lower. The majority of anti-HBc positive individuals acquire HBV surface antibody (anti-HBs) through natural clearance of illness or as a result of HBV vaccination. However, an anti-HBs level that clearly precludes the blood circulation of HBV DNA and disease transmission has not yet been clearly recognized. We attempted to address these issues by analysing the seroprevalence of HBV DNA in HBsAg bad, anti-HBc positive healthy blood donors with varying levels of anti-HBs antibody. Blood donors in our tertiary care hospital in south India were recruited in October 2008. Serum samples from these donors were tested for HBsAg, HIV and HCV antibody using Vitros ECI (Ortho-Clinical Diagnostics, Corilagin Raritan, NJ, USA). A total of 1 1,300 alternative blood donors bad for these serological markers were investigated for the presence of anti-HBc antibody (Diasorin S.p.A. Saluggia, Italy). All the samples that were confirmed to become anti-HBc positive in Architect Anti-HBc II (Abbott, Weisbaden, Germany) were further tested for anti-HBs levels (AxSYM, Abbott, Weisbaden, Germany) and categorised into three organizations relating to these levels: anti-HBs bad, anti-HBs <100 mIU/mL and anti-HBs >100 mIU/mL. DNA was extracted from 200 L of plasma using the QIAamp DNA blood MiniKit (Qiagen GmbH, Hilden, Germany) and HBV DNA was Corilagin quantified using a CE-marked artusHBV RG real-time polymerase chain reaction (PCR) (Qiagen GmbH, Hilden, Germany) in the Rotor-Gene 3,000 or 6,000 platform (Corbett Study, Mortlake, Australia). The assay focuses on the 134 bp region of the HBV core gene and the lower limit of detection (LLD) stated by the manufacturer is definitely 20 IU/mL (system 1). Samples were further tested by another sensitive, FDA approved automated nucleic acid system (Abbott RealTime HBV, Weisbaden, Germany) focusing on the surface region of the HBV genome. The LLD in this case is definitely 10 IU/mL with a sample input of 500 L (system 2). The study was authorized by the Institutional Review Table of the hospital. The median age of the study donors was 32 (range, 1465) years and most of the donor were male (89%). Of 1300 samples tested for anti-HBc, 217 (16.7%) were confirmed to be positive. When these anti-HBc positive blood donors were tested for anti-HBs, 86 (39.6%) were anti-HBs negative, 58 (26.7%) had an anti-HBs titre <100 mIU/mL and 73 (33.6%) donors had an anti-HBs titre of >100 mIU/mL. The available 184 samples from your anti-HBc seropositive blood donors were tested for HBV DNA and all were negative on screening in system 1 (artusHBV RG PCR). When all these samples were further tested in the automated nucleic acid system 2 (Abbott RealTime HBV), two samples were found to be positive for HBV DNA having a viral weight of <10 IU/mL (Number 1). The overall prevalence of occult HBV in anti-HBc seropositive individuals was therefore 1.1%. == Number 1. == Circulation Chart of the Study. Of the two HBV DNA positive donor samples, the anti-HBs titer of one sample was 63 mIU/mL and the additional sample was anti-HBs bad. Previous reports possess recorded a prevalence of occult HBV of 7.5 to 30% in India25. In contrast, here we found a Corilagin prevalence of 1 1.1% occult HBV in anti-HBc seropositive healthy blood donors. Such a Rabbit Polyclonal to Dyskerin low rate of occult HBV illness from a region of intermediate endemicity for HBV is definitely noteworthy. The variations in rates of occult HBV seen in this populace questions the uniformity of our screening practices. Though most studies have used sensitive nested PCR, HBsAg assays used in the analysis of occult HBV are highly varied (Table.